Princeton University.
J Health Polit Policy Law. 2024 Feb 1;49(1):99-132. doi: 10.1215/03616878-10910224.
This study investigates South Korea's trials and errors in procuring COVID-19 vaccines from abroad, amid the limitations of a multilateral scheme for global provision through the COVID-19 Vaccines Global Access (COVAX) program via the World Health Organization (WHO) and the discussions on COVID-19 vaccine patent waivers at the World Trade Organization. Using the framework of "self-help" in the international system and country categorization to explicate country behaviors by state-business relations and expertise to explain South Korea's COVID-19 vaccine procurement process, this study argues that in the absence of a global mechanism that guarantees adequate and timely vaccine provision, countries are left to the sole option of depending on their own capabilities: expertise, budget, and policy planning by consolidating public and private capacities to acquire vaccines for the public. To support the argument, an in-depth case investigation of South Korea's Vaccine Procurement Task Force is presented. The case study focuses on the policy assessment of critical elements in South Korea's vaccine procurement and rollout on facing obstacles to sufficient procurement through COVAX: decision-making impacting the timing and dosage of procurement, diplomatic and business channels to sign bilateral contracts, setup of a smart-factory vaccination hub, and indigenous vaccine development for WHO approval.
本研究考察了韩国在通过世界卫生组织(WHO)的 COVID-19 疫苗全球获取(COVAX)计划等多边方案获取 COVID-19 疫苗方面的尝试和错误,以及在世界贸易组织(WTO)讨论 COVID-19 疫苗专利豁免的情况下。本研究使用国际体系中的“自助”框架和国家分类,通过国家-企业关系和专业知识来解释国家行为,以解释韩国的 COVID-19 疫苗采购过程,认为在缺乏保证充足和及时疫苗供应的全球机制的情况下,各国只能依靠自己的能力:通过整合公共和私人能力为公众获取疫苗,来巩固专业知识、预算和政策规划。为了支持这一论点,对韩国疫苗采购工作队进行了深入的案例调查。案例研究侧重于评估韩国疫苗采购和推出过程中面临的关键因素:通过 COVAX 进行充分采购的决策影响采购的时机和剂量、签署双边合同的外交和商业渠道、建立智能工厂疫苗接种中心以及为获得世卫组织批准的本土疫苗开发。